Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Payables (2020 - 2025)

Bioventus (BVS) has disclosed Payables for 6 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 53.87% year-over-year to $10.9 million, compared with a TTM value of $10.9 million through Dec 2025, down 53.87%, and an annual FY2025 reading of $10.9 million, down 53.87% over the prior year.
  • Payables was $10.9 million for Q4 2025 at Bioventus, down from $26.6 million in the prior quarter.
  • Across five years, Payables topped out at $41.4 million in Q3 2023 and bottomed at $10.3 million in Q2 2021.
  • Average Payables over 5 years is $22.8 million, with a median of $22.8 million recorded in 2022.
  • The sharpest move saw Payables skyrocketed 282.52% in 2021, then tumbled 53.87% in 2025.
  • Year by year, Payables stood at $16.9 million in 2021, then surged by 116.95% to $36.7 million in 2022, then crashed by 37.22% to $23.0 million in 2023, then grew by 2.83% to $23.7 million in 2024, then crashed by 53.87% to $10.9 million in 2025.
  • Business Quant data shows Payables for BVS at $10.9 million in Q4 2025, $26.6 million in Q3 2025, and $24.2 million in Q2 2025.